|
1
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sabe H: Cancer early dissemination:
Cancerous epithelial-mesenchymal transdifferentiation and
transforming growth factor β signalling. J Biochem. 149:633–639.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akira S, Takeda K and Kaisho T: Toll-like
receptors: Critical proteins linking innate and acquired immunity.
Nat Immunol. 2:675–680. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sato Y, Goto Y, Narita N and Hoon DS:
Cancer cells expressing toll-like receptors and the tumor
microenvironment. Cancer Microenviron. 2:(Suppl 1). 205–214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chochi K, Ichikura T, Kinoshita M, Majima
T, Shinomiya N, Tsujimoto H, Kawabata T, Sugasawa H, Ono S, Seki S,
et al: Helicobacter pylori augments growth of gastric
cancers via the lipopolysaccharide-toll-like receptor 4 pathway
whereas its lipopolysaccharide attenuates antitumor activities of
human mononuclear cells. Clin Cancer Res. 14:2909–2917. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukata M, Chen A, Vamadevan AS, Cohen J,
Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, et
al: Toll-like receptor-4 promotes the development of
colitis-associated colorectal tumors. Gastroenterology.
133:1869–1881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou M, McFarland-Mancini MM, Funk HM,
Husseinzadeh N, Mounajjed T and Drew AF: Toll-like receptor
expression in normal ovary and ovarian tumors. Cancer Immunol
Immunother. 58:1375–1385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li
JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide
3-kinase/Akt pathway plays an important role in chemoresistance of
gastric cancer cells against etoposide and doxorubicin induced cell
death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu RY, Chan CH, Spicer JD, Rousseau MC,
Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in
human colorectal cancer cells increases beta1 integrin-mediated
cell adhesion and liver metastasis. Cancer Res. 71:1989–1998. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shayesteh L, Lu Y, Kuo WL, Baldocchi R,
Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW:
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet.
21:99–102. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sham JS, Tang TC, Fang Y, Sun L, Qin LX,
Wu QL, Xie D and Guan XY: Recurrent chromosome alterations in
primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet.
133:39–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeong JY, Kim KS, Moon JS, Song JA, Choi
SH, Kim KI, Kim TH and An HJ: Targeted inhibition of phosphatidyl
inositol-3-kinase p110β, but not p110α, enhances apoptosis and
sensitivity to paclitaxel in chemoresistant ovarian cancers.
Apoptosis. 18:509–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurosaki T, Takata M, Yamanashi Y, Inazu
T, Taniguchi T, Yamamoto T and Yamamura H: Syk activation by the
Src-family tyrosine kinase in the B cell receptor signaling. J Exp
Med. 179:1725–1729. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beitz LO, Fruman DA, Kurosaki T, Cantley
LC and Scharenberg AM: SYK is upstream of phosphoinositide 3-kinase
in B cell receptor signaling. J Biol Chem. 274:32662–32666. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ,
Do IG, Song SY, Lee YY, Choi CH, Kim TJ, et al: High galectin-1
expression correlates with poor prognosis and is involved in
epithelial ovarian cancer proliferation and invasion. Eur J Cancer.
48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC,
Martinez DG, Engle X, Gewirtz AT, Ahonen CL and Conejo-Garcia JR:
In situ stimulation of CD40 and Toll-like receptor 3 transforms
ovarian cancer-infiltrating dendritic cells from immunosuppressive
to immunostimulatory cells. Cancer Res. 69:7329–7337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scarlett UK, Rutkowski MR, Rauwerdink AM,
Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC,
Gonzalez JL, Weaver J, et al: Ovarian cancer progression is
controlled by phenotypic changes in dendritic cells. J Exp Med.
209:495–506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan
QM, Ye F, Li R, Gao L, Zhao QD, et al: Toll like receptor 4
facilitates invasion and migration as a cancer stem cell marker in
hepatocellular carcinoma. Cancer Lett. 358:136–143. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kelly MG, Alvero AB, Chen R, Silasi DA,
Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G: TLR-4
signaling promotes tumor growth and paclitaxel chemoresistance in
ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alberts DS, Liu PY, Hannigan EV, O'Toole
R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya
VK, DuBeshter B, et al: Intraperitoneal cisplatin plus intravenous
cyclophosphamide versus intravenous cisplatin plus intravenous
cyclophosphamide for stage III ovarian cancer. N Engl J Med.
335:1950–1955. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Byrd-Leifer CA, Block EF, Takeda K, Akira
S and Ding A: The role of MyD88 and TLR4 in the LPS-mimetic
activity of Taxol. Eur J Immunol. 31:2448–2457. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szajnik M, Szczepanski MJ, Czystowska M,
Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M and
Whiteside TL: TLR4 signaling induced by lipopolysaccharide or
paclitaxel regulates tumor survival and chemoresistance in ovarian
cancer. Oncogene. 28:4353–4363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Laird MH, Rhee SH, Perkins DJ, Medvedev
AE, Piao W, Fenton MJ and Vogel SN: TLR4/MyD88/PI3K interactions
regulate TLR4 signaling. J Leukoc Biol. 85:966–977. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang S, Bader AG and Vogt PK:
Phosphatidylinositol 3-kinase mutations identified in human cancer
are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schöndorf T, Göhring UJ, Roth G, Middel I,
Becker M, Moser N, Valter MM and Hoopmann M: Time to progression is
dependent on the expression of the tumour suppressor PTEN in
ovarian cancer patients. Eur J Clin Invest. 33:256–260. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Kristensen GB, Helland A, Nesland
JM, Børresen-Dale AL and Holm R: Protein expression and prognostic
value of genes in the erb-b signaling pathway in advanced ovarian
carcinomas. Am J Clin Pathol. 124:392–401. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sher I, Adham SA, Petrik J and Coomber BL:
Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma
cells from anoikis. Int J Cancer. 124:553–561. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Satelli A and Rao US: Galectin-1 is
silenced by promoter hypermethylation and its re-expression induces
apoptosis in human colorectal cancer cells. Cancer Lett. 301:38–46.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ito K and Ralph SJ: Inhibiting galectin-1
reduces murine lung metastasis with increased CD4(+) and CD8(+) T
cells and reduced cancer cell adherence. Clin Exp Metastasis.
29:561–572. 2012. View Article : Google Scholar : PubMed/NCBI
|
